France (FR)

Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference? (2018) Merola E, Zandee W, De Mestier L, Klumpen HJ, Geboes KP, Poczkaj K, W DH, Munir A Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Does the Beneficial Antipruritic Effect of Bezafibrate in Primary Biliary Cholangitis Depend on Autotaxin Activity? (2018) Kremer A, Le Cleac'H A, Wolf K, Chazouilleres O, Lemoinne S, De Chaisemaitin L, Chollet-Martin S, et al. Conference contribution Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis (2018) Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, et al. Journal article BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS (2018) Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, et al. Journal article Evolution of the Ligand Shell Around Small ZnO Nanoparticles During the Exchange of Acetate by Catechol: A Small Angle Scattering Study (2018) Schindler T, Lin W, Schmutzler T, Lindner P, Peukert W, Segets D, Unruh T Journal article, Original article